<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156299</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000540303</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>020201</secondary_id>
    <nct_id>NCT00156299</nct_id>
  </id_info>
  <brief_title>Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate</brief_title>
  <official_title>A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors learn more about changes that occur in cancer cells. It may also help doctors
      understand how cancer cells respond to treatment with choline magnesium trisalicylate.

      PURPOSE: This pilot clinical trial is studying gene expression in cancer cells during
      chemotherapy and the safety of choline magnesium trisalicylate in treating patients with
      newly diagnosed acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine temporal changes in leukemic cell NF-kB activity when choline magnesium
           trisalicylate is administered during induction chemotherapy in patients with newly
           diagnosed acute myeloid leukemia.

        -  Determine toxicities of this regimen in these patients.

      Secondary

        -  Determine patterns of leukemic cell gene expression in patients treated with this
           regimen.

        -  Determine if NF-kB modulation results in enhanced apoptosis in patients treated with
           this regimen.

      OUTLINE: This is an open-label, pilot study.

      Patients receive oral choline magnesium trisalicylate every 8 hours for 48 hours or
      dexamethasone every 6 hours for 48 hours plus choline magnesium trisalicylate every 8 hours
      for 48 hours during induction chemotherapy as determined by the primary physician.

      Blood is collected at baseline, 24 hours, and 48 hours to assess for changes in NF-kB
      expression, apoptosis, and gene expression in leukemic cells.

      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Replaced by another study
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporal changes in leukemic cell NF-kB activity</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of leukemic cell gene expression after administration of choline magnesium trisalicylate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis related to NF-kB modulation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone plus Choline Magnesium Trisalicylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone plus Choline Magnesium Trisalicylate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Choline Magnesium Trisalicylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choline Magnesium Trisalicylate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>choline magnesium trisalicylate</intervention_name>
    <description>1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.</description>
    <arm_group_label>Dexamethasone plus Choline Magnesium Trisalicylate</arm_group_label>
    <arm_group_label>Choline Magnesium Trisalicylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.</description>
    <arm_group_label>Dexamethasone plus Choline Magnesium Trisalicylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed acute myeloid leukemia

               -  Newly diagnosed disease

          -  Presence of cytogenetic abnormalities must be determined by standard cytogenetics with
             or without FISH studies

          -  Leukemic blast count &gt; 5,000/mmÂ³ of peripheral blood

          -  No acute promyelocytic leukemia (M3)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Bilirubin &lt; 2.0 times upper limit of normal (ULN)

          -  AST &lt; 3.0 times ULN

          -  Creatinine &lt; 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled psychiatric illness that, in the opinion of the principal
             investigator, would preclude study compliance

          -  No other concurrent medical condition that would preclude study compliance

          -  No allergies to any investigational drugs and/or chemotherapeutic agents

          -  No upper or lower gastrointestinal (GI) related hemorrhage within the past 6 months as
             determined by endoscopy

               -  No clinical diagnosis of GI bleeding requiring blood transfusions

        PRIOR CONCURRENT THERAPY:

          -  No prior induction therapy

          -  No prior chemotherapy for acute leukemia

          -  No concurrent medications that would preclude study compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Strair, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, Lin HC, Lin Y, Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. Clin Cancer Res. 2008 Nov 15;14(22):7564-8. doi: 10.1158/1078-0432.CCR-08-1390.</citation>
    <PMID>19010875</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Choline magnesium trisalicylate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Choline</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

